Jaguar Animal Health Inc (NASDAQ:JAGX) has announced the signing of a distribution agreement, with JP Equine Services. The agreement would cover two non-prescription products from the company and would be distributed in Japan. Neonorm Foal and Neonorm Calf, the products in question, are natural, clinically tested, non-drug products that would be used as anti-diarrheal for newborn horses. JAGX pointed out that diarrhea is one of the most common complains in newborn horses, particularly during the first 30-days, after birth.
Discussing the market in Japan, the company noted that it is a country where 21,000 horse races are held annually and was estimated to be home to 115,000 horses, in 2000. Moreover, according to figures from the Japan dairy council, there are approximately 1.45 million dairy cattle, in the country, as of 2012. Recently, the demand for dairy products has started to surge, in Japan, which would mean more healthy dairy animals are needed, as well.
Earlier in April, JAGX issued a commercial update, for its shareholders, stating that it would be launching an advertising campaign, during April 2017, for its Neonorm products. Jaguar noted that the TV advertisements would run in specific target markets, particularly in key dairy market areas. As such, the company has engaged RFD-TV, to air JAGX’s 30-second commercials, which would air during Prime Time hours. It should be noted here that RFD-TV is a 24-hour television network, which also airs content related to agribusiness and rural lifestyle.
In addition to this, the company has also engaged DairyLine, a radio program that airs during the early morning hours. DairyLine has agreed to grant 30-second spots, for the Neonorm Calf commercial. The radio program was chosen because of its popularity amongst the dairy community. The show is considered to be the premiere radio voice of the dairy industry and has been airing for over 20-years.
Jaguar Animal Health Inc (NASDAQ:JAGX) completed the May 2 trading session with a decline of 4.64%, to its share value, to close at $0.82 per share.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.